Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZANEVO
NCT06959511Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanzalintinib in thyroid cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Objective Response Rate and Safety and adverse events at 6 months. Started Jul 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT06959511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959511.